SAN DIEGO -- (BUSINESS WIRE) -- OncoSec Medical Inc. (OTCQB:ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, has appointed Dr. Soldano Ferrone, M.D., Ph.D., to the company’s Scientific Advisory Board. Dr. Ferrone is an internationally renowned expert in tumor immunology, and will contribute his considerable expertise to the company as it works to advance an expanding intratumoral immunotherapy pipeline.
Dr. Ferrone’s research program focuses on the characterization of escape mechanisms deployed by tumor cells to avoid immune-mediated recognition and destruction. He has also studied how combined immunotherapeutic strategies can counteract these tumor escape mechanisms. These studies are greatly facilitated by the large panel of HLA antigen- and human tumor antigen-specific monoclonal antibodies he has developed and shared with the scientific community over the years.
He has described the results of his studies in more than 600 papers published in peer-reviewed journals. Moreover he has been the editor of 14 books and the guest editor of five special issues of oncology journals.
“Dr. Ferrone brings considerable expertise to our growing panel of distinguished experts and key opinion leaders,” said Punit Dhillon, President and CEO. “We believe his guidance will prove invaluable as we work to advance our immune oncology pipeline and establish OncoSec as a leader in intratumoral immunotherapy.”
Dr. Ferrone received his M.D. and Ph.D. degrees in 1964 and in 1971, respectively, from the University of Milan, Milan, Italy. He has held faculty positions at the University of Milan, Scripps Clinic and Research Foundation, La Jolla, CA, Columbia University, New York, NY, New York Medical College, Valhalla, NY, Roswell Park Cancer Institute, Buffalo, NY and at the University of Pittsburgh School of Medicine, Pittsburgh, PA. Since 2012 he has been a faculty member of the Department of Surgery at Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Dr. Ferrone has received numerous awards and honors. For the last 30 years he has been a member of many review committees including NIH Study Sections, and of the editorial boards of many scientific journals. Furthermore he is a member of several external scientific advisory boards.
“Long before immuno-oncology was recognized as an important field, Soldano was in the forefront of the attempt to understand how tumors subvert the immune system — particularly, how they disrupt normal mechanisms of antigen processing and presentation,” said Dr. Robert Pierce, M.D., Chief Medical Officer. “We believe Soldano’s expertise will help us further define the mechanism by which intratumoral electroporation of IL-12 leads to a reversal of these pathologic defects and augments immunogenicity.”
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its ImmunoPulse immunotherapy to treat solid tumors. OncoSec Medical's core technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of IL-12 and other DNA-based immune-modulating agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec's clinical programs currently include three Phase 2 trials targeting metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma. As the company continues to evaluate ImmunoPulse in these indications, it is also investigating additional indications and combination therapeutic approaches. For more information, please visit www.oncosec.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.